Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTIEqUE Study: Nivolumab plus trifluridine/tipiracil in third-line or later gastric/EGJ adenocarcinoma
jRCTs031260251Phase 2Recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and trifluridine + tipiracil in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Disease Control Rate. Started Jul 2026; status: recruiting.
02
Drugs
nivolumabtrifluridine + tipiracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs031260251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260251.